These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
424 related items for PubMed ID: 19064987
1. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, Ciccarelli BT, Sacco A, Ioakimidis L, Adamia S, Moreau AS, Patterson CJ, Ghobrial IM, Treon SP. J Clin Oncol; 2009 Jan 10; 27(2):250-5. PubMed ID: 19064987 [Abstract] [Full Text] [Related]
2. Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy. Leleu X, Tamburini J, Roccaro A, Morel P, Soumerai J, Lévy V, Wemeau M, Balkaran S, Poulain S, Hunter ZR, Ghobrial IM, Treon SP, Leblond V. Clin Lymphoma Myeloma; 2009 Mar 10; 9(1):71-3. PubMed ID: 19362978 [Abstract] [Full Text] [Related]
3. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Andresen S, Kuczkowski E, Bolwell B. J Clin Oncol; 2006 Aug 01; 24(22):3604-10. PubMed ID: 16877727 [Abstract] [Full Text] [Related]
4. [Treatment of Waldenström macroglobulinaemia--the experience of one centre]. Adam Z, Pour L, Krejcí M, Korístek Z, Navrátil M, Krivanová A, Zahradová L, Hájek R. Vnitr Lek; 2009 Jan 01; 55(1):9-17. PubMed ID: 19227950 [Abstract] [Full Text] [Related]
5. [Study on the transformation from myelodysplastic syndromes into acute leukemias]. Shi J, Shao Z, Liu H, Li K, Song L, Zhang Y, Zheng Y, Chen G, Chu Y, He H, Zhao M, He G, Feng B, Hao Y, Yang T, Yang C. Zhonghua Xue Ye Xue Za Zhi; 2001 Jul 01; 22(7):351-4. PubMed ID: 11877096 [Abstract] [Full Text] [Related]
6. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG. J Clin Oncol; 2013 Jan 20; 31(3):301-7. PubMed ID: 23233721 [Abstract] [Full Text] [Related]
7. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Carney DA, Westerman DA, Tam CS, Milner A, Prince HM, Kenealy M, Wolf M, Januszewicz EH, Ritchie D, Came N, Seymour JF. Leukemia; 2010 Dec 20; 24(12):2056-62. PubMed ID: 20962860 [Abstract] [Full Text] [Related]
8. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Luminari S, Lombardo M, Buda G, Lazzaro A, Gobbi PG, Stelitano C, Morabito F, Quarta G, Brugiatelli M. Haematologica; 2008 Mar 20; 93(3):398-404. PubMed ID: 18268277 [Abstract] [Full Text] [Related]
9. [Haematological malignancies: incidence in Basse-Normandie, France, for 1997-2004]. Troussard X, Duchenet V, Cornet E, Mouchel D, Malet M, Collignon A. Rev Epidemiol Sante Publique; 2009 Jun 20; 57(3):151-8. PubMed ID: 19375876 [Abstract] [Full Text] [Related]
10. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A, Schwartz CL. J Clin Oncol; 2007 Feb 10; 25(5):493-500. PubMed ID: 17290056 [Abstract] [Full Text] [Related]
11. Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenström's macroglobulinemia after sequential treatment with chlorambucil and fludarabine. Shin SJ, Chun SH, Kim KO, Kim MK, Lee KH, Hyun MS, Cho HS. Jpn J Clin Oncol; 2005 Oct 10; 35(10):622-5. PubMed ID: 16172172 [Abstract] [Full Text] [Related]
12. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Sehn LH, Shenkier TN, Gascoyne RD, Connors JM. J Clin Oncol; 2008 Nov 10; 26(32):5165-9. PubMed ID: 18838711 [Abstract] [Full Text] [Related]
13. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation. Abdelhameed A, Pond GR, Mitsakakis N, Brandwein J, Chun K, Gupta V, Kamel-Reid S, Lipton JH, Minden MD, Schimmer A, Schuh A, Yee K, Messner HA. Cancer; 2008 Apr 01; 112(7):1513-21. PubMed ID: 18286528 [Abstract] [Full Text] [Related]
14. Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Clinicopathologic features of 12 cases. Lin P, Mansoor A, Bueso-Ramos C, Hao S, Lai R, Medeiros LJ. Am J Clin Pathol; 2003 Aug 01; 120(2):246-53. PubMed ID: 12931555 [Abstract] [Full Text] [Related]
15. Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants. Kornblit B, Masmas T, Madsen HO, Ryder LP, Svejgaard A, Jakobsen B, Sengeløv H, Olesen G, Heilmann C, Dickmeiss E, Petersen SL, Vindeløv L. Bone Marrow Transplant; 2008 May 01; 41(10):851-9. PubMed ID: 18246114 [Abstract] [Full Text] [Related]
16. Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation? Ling S, Joshua DE, Gibson J, Young G, Iland H, Watson G, Ho PJ. Am J Hematol; 2006 Feb 01; 81(2):110-4. PubMed ID: 16432856 [Abstract] [Full Text] [Related]
17. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Larson RA, Schiffer CA. J Clin Oncol; 2002 Sep 15; 20(18):3878-84. PubMed ID: 12228208 [Abstract] [Full Text] [Related]
18. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML. Nevill TJ, Hogge DE, Toze CL, Nantel SH, Power MM, Abou Mourad YR, Song KW, Lavoie JC, Forrest DL, Barnett MJ, Shepherd JD, Nitta JY, Wong S, Sutherland HJ, Smith CA. Bone Marrow Transplant; 2008 Nov 15; 42(10):659-66. PubMed ID: 18679372 [Abstract] [Full Text] [Related]
19. Leukemia incidence following primary breast carcinoma treatment. Kaplan HG, Malmgren JA, Atwood M. Cancer; 2004 Oct 01; 101(7):1529-36. PubMed ID: 15378478 [Abstract] [Full Text] [Related]
20. Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphoma. Basecke J, Podleschny M, Becker A, Seiffert E, Schwiers I, Schwiers R, Haase D, Glass B, Schmitz N, Trumper L, Griesinger F. Br J Haematol; 2008 Apr 01; 141(1):52-9. PubMed ID: 18324966 [Abstract] [Full Text] [Related] Page: [Next] [New Search]